Passage Bio Inc
NASDAQ:PASG
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.5050
  • TODAY'S CHANGE (%)
    -0.0310 (-5.7836%)
  • Bid / Lots
    0.5010/ 1
  • Ask / Lots
    0.5186/ 13
  • Open / Previous Close
    0.5400 / 0.5360
  • Day Range
    0.5000
    0.5613
  • 52 Week Range
    0.4510
    1.7900
  • Volume
    400,277

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
PASG
Passage Bio Inc
31.2M
-0.4x
---
RNXT
RenovoRx Inc
30.9M
-2.3x
---
ALTS
ALT5 Sigma Corp
30.8M
-0.6x
---
CMMB
Chemomab Therapeutics Ltd
30.5M
-1.7x
---
LIANY
LianBio
32.2M
-0.4x
---
CERO
CERo Therapeutics Holdings Inc
32.2M
-0.6x
---
As of 2024-11-23

Company Information

Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its clinical product candidate, PBFT02, seeks to elevate progranulin levels to restore lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus capsid to deliver a functional granulin gene, or GRN, encoding progranulin to the brain via intra cisterna magna administration. The lead indication for PBFT02 is frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-GRN. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.

Contact Information

Headquarters
One Commerce Square 2005 Market Street, 39Th FloorPHILADELPHIA, PA, United States 19103
Phone
267-866-0312
Fax
302-655-5049

Executives

Independent Chairwoman of the Board
Maxine Gowen
President, Chief Executive Officer, Director
William Chou
Chief Financial Officer
Kathleen Borthwick
Chief Scientific Officer
Susan Browne
General Counsel, Company Secretary
Edgar Cale

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$31.2M
Revenue (TTM)
$0.00
Shares Outstanding
61.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.16
EPS
$-1.17
Book Value
$2.03
P/E Ratio
-0.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.